Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer
Liquid biopsy findings from a prospective Oesophageal Cancer Classification and Molecular Stratification Consortium study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
Efficacy of selinexor in combination with bortezomib and dexamethasone was evaluated in the BOSTON study
FDA Approves Relugolix for Advanced Prostate Cancer
Efficacy was evaluated in HERO study
FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Mutations
Efficacy was demonstrated in ADAURA study
FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer
Evidence for efficacy was evaluated in SOPHIA study
EMA Recommends Granting a Marketing Authorisation for Fedratinib
JAK inhibitor is intended for the treatment of primary myelofibrosis and of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia
EMA Recommends Granting a Marketing Authorisation for Tucatinib
It is intended for the treatment of HER2-positive locally advanced or metastatic breast cancer
EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Moxetumomab Pasudotox
It is intended for the treatment of relapsed or refractory hairy cell leukaemia
EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib
Sunitinib Accord is a generic of Sutent, which has been authorised in the EU since 2006
EMA Recommends Extension of Indications for Avelumab
New indication concerns the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma
EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib
It is intended for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan
It is intended for the treatment of metastatic HER2-positive breast cancer